Aligos Therapeutics/$ALGS
About Aligos Therapeutics
Ticker
Industry
Employees
ALGS Metrics
$127M
-
-$12.89
2.73
-
Price and volume
Market cap
$127M
Beta
2.73
52-week high
$46.80
52-week low
$6.76
Average daily volume
449K
Financial strength
Current ratio
3.809
Quick ratio
3.575
Long term debt to equity
11.444
Total debt to equity
18.231
Management effectiveness
Return on assets (TTM)
-67.32%
Return on equity (TTM)
-146.69%
Valuation
Price to revenue (TTM)
34.175
Price to book
2.28
Price to tangible book (TTM)
2.28
Price to free cash flow (TTM)
-2.408
Growth
Revenue change (TTM)
-63.40%
Earnings per share change (TTM)
-72.78%
3-year revenue growth (CAGR)
14.53%
3-year earnings per share growth (CAGR)
-46.45%
ALGS News
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
FAQs
What’s the current market cap for Aligos Therapeutics stock?
What is the P/E ratio for Aligos Therapeutics stock?
Does Aligos Therapeutics stock pay dividends?
No, Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders as of January 15, 2025.
When is the next Aligos Therapeutics dividend payment date?
Aligos Therapeutics (ALGS) stock does not pay dividends to its shareholders.
What is the beta indicator for Aligos Therapeutics?
Aligos Therapeutics (ALGS) has a beta rating of 2.73. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.